Apurva K. Srivastava

Also affiliated with Frederick National Laboratory for Cancer Research

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial”.

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Nature Medicine(2025)10.1038/s41591-024-03361-4

N/A

0.954DataRank · unranked

41 citations

Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin +30 more

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0566

N/A

0.475DataRank · unranked

11 citations

Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O’Sullivan Coyne, Andrea M. Gross +7 more

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

Investigational New Drugs(2021)10.1007/s10637-021-01138-x

N/A

0.312DataRank · unranked

7 citations

Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young Ho Lee, Donald P. Bottaro +11 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more

Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo

Redox Biology(2023)10.1016/j.redox.2023.102650

N/A

0DataRank · unranked

50 citations

Alexandr A. Kapralov, Vladimir A. Tyurin, Galina V. Shurin, Andrew A. Amoscato, Dhivyaa Rajasundaram +10 more

Optimization of 1,2,4-Triazole-Based p97 Inhibitors for the Treatment of Cancer

ACS Medicinal Chemistry Letters(2023)10.1021/acsmedchemlett.3c00163

N/A

0DataRank · unranked

12 citations

Celeste Alverez, Alexander Chatterley, Marina Kovaliov, Evan J. Carder, Michael J. Houghton +16 more

Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-22-0167

N/A

0DataRank · unranked

10 citations

Christina Mazcko, Timothy M. Fan, David M. Vail, Brian K. Flesner, Jeffrey N. Bryan +14 more

Redox Epiphospholipidome in Programmed Cell Death Signaling: Catalytic Mechanisms and Regulation

Frontiers in Endocrinology(2021)10.3389/fendo.2020.628079

N/A

0DataRank · unranked

35 citations

Yulia Y. Tyurina, Irina I. Vlasova, Alexander A. Kapralov, Andrew A. Amoscato, Tamil S. Anthonymuthu +12 more

Development and validation of an LC–MS/MS generic assay platform for small molecule drug bioanalysis

Journal of Pharmaceutical and Biomedical Analysis(2021)10.1016/j.jpba.2021.114185

N/A

0DataRank · unranked

7 citations

Joseph M. Covey, Melinda G. Hollingshead, Apurva K. Srivastava, Timothy W. Synold, Jan H. Beumer +1 more